UCART19
Phase 1Cell therapy
Institut de Recherches Internationales ServierUCART19 is one of 60 biologic programs targeting Lymphoid Leukemia. It is currently in Phase 1.
2
Indications
3
Total Trials
1
Active Trials
59
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
408 competitors in Acute Lymphoblastic Leukemia
#DrugCompanyPhaseTrials
1Rituxan
RochePhase 3
Oncovin
EEastern Cooperative Oncology Group
Phase 3
Medrol
PfizerPhase 3
Arranon
NovartisPhase 3
Eptanemab
UCBPhase 3
Leukine
SanofiPhase 3
Alkeran
AApotex Inc.
Phase 3
Zinecard
CChildren's Oncology Group
Phase 3
Roferon-a
RochePhase 3
Luye
Ascentage Pharma Group Inc.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Lymphoid Leukemia1 trial
A Study to Evaluate the Long-term Safety of Patients With Advanced Lymphoid Leukemia Who Have Been Previously Administered With UCART19
Active, not recruiting·Institut de Recherches Internationales Servier·Phase 1·NCT02735083·28 enrolled
Institut de Recherches Internationales Servier·Phase 1·NCT02735083·28 enrolledAcute Lymphoblastic Leukaemia1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for UCART19. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details